GS
TBPH icon

GTS Securities’s Theravance Biopharma TBPH Stock Holding History

GTS Securities’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$430K Buy
+25,320
New +$419K 0.01% 788

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

GTS Securities's TBPH Position: Q2 2026 in Review

GTS Securities opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 25,320 shares worth $430K. The stake represents 0.01% of the portfolio and ranks #788 among its holdings.

179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • GTS Securities held 25,320 shares of Theravance Biopharma worth $430K as of Q2 2026.
  • Theravance Biopharma was a new GTS Securities position in Q2 2026.
  • Theravance Biopharma made up 0.01% of GTS Securities's portfolio in Q2 2026, its #788 holding.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on GTS Securities's 13F filing for Q2 2026, filed 14 Aug 2026.